ReviewAntibodies (Basel, Switzerland)2019
Peptides for Infectious Diseases: From Probe Design to Diagnostic Microarrays.
Review in Antibodies (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Synthetic short peptide mimicking IsdB and IsdH conserved motifs selectively bind and enable detection ofFrontiers in immunology · 2026Article
- Strong antibody reactivity to HIV-1 synthetic peptides in seropositive indigenous Warao peopleBiomedica : revista del Instituto Nacional de Salud · 2025Article
- Transformer-based deep learning enables improved B-cell epitope prediction in parasitic pathogens: A proof-of-concept study on Fasciola hepatica.PLoS neglected tropical diseases · 2025Article
- Disposable electrochemical platform based on solid-binding peptides and carbon nanomaterials: an alternative device for leishmaniasis detection.Mikrochimica acta · 2023Article
- B-Cell Epitope Mapping of TprC and TprD Variants ofFrontiers in immunology · 2022Article
- Unravelling the antimicrobial activity of peptide hydrogel systems: current and future perspectives.Soft matter · 2021Review
- Exploring peptide studies related to SARS-CoV to accelerate the development of novel therapeutic and prophylactic solutions against COVID-19.Journal of infection and public health · 2021Review
- Immunogenic Peptides from Pap31 and SCS-α ofPathogens (Basel, Switzerland) · 2021Article
- Article
- SARS-CoV-2 Epitope Mapping on Microarrays Highlights Strong Immune-Response to N Protein Region.Vaccines · 2021Article
- Antibodies as Diagnostic Targets and as Reagents for Diagnostics.Antibodies (Basel, Switzerland) · 2020Article
- Scoping review of the applications of peptide microarrays on the fight against human infections.PloS oneArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Peptides and peptidomimetics have attracted revived interest regarding their applications in chemical biology over the last few years. Their chemical versatility, synthetic accessibility and the ease of storage and management compared to full proteins have made peptides particularly interesting in diagnostic applications, where they proved to efficiently recapitulate the molecular recognition properties of larger protein antigens, and were proven to be able to capture antibodies circulating in the plasma and serum of patients previously exposed to bacterial or viral infections. Here, we describe the development, integration and application of strategies for computational prediction and design, advanced chemical synthesis, and diagnostic deployment in multiplexed assays of peptide-based materials which are able to bind antibodies of diagnostic as well as therapeutic interest. By presenting successful applications of such an integrated strategy, we argue that they will have an ever-increasing role in both basic and clinical realms of research, where important advances can be expected in the next few years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.